“Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605)”, J of Skin, vol. 10, no. 2, p. s746, Mar. 2026, doi: 10.25251/nq0ynj58.